EGFR and neoplasm: Because numerous studies have shown increased cisplatin sensitivity after inhibition of EGFR, HER2/neu or VEGFR in different tumor entities, we performed combination assays despite the relative resistance of our investigated cell lines towards AEE788 [74,75].